ResearchPDF Available

Recommendation:Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D, Saunders MP, AVEX study investigators

Authors:

Recommendation of a study that confirm the efficacy of a combinatio drugs in colon cancer

Content may be subject to copyright.

Bevacizumab plus capecitabine versus

capecitabine alone in elderly patients with

previously untreated metastatic colorectal

cancer (AVEX): an open-label, randomised

phase 3 trial.

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S,

Andre N, Waterkamp D, Saunders MP, AVEX study investigators

show author affiliations

Lancet Oncol. 2013 Oct; 14(11):1077-85

Conclusion of recomandation:” The good results obtained in this study are important for clinical

practice, but we should use, in my opinion, geriatric assessment, and we have to select the

patients very carefully. Bevacizumab plus capecitabine could be used in elderly patients with

advanced colon cancer for whom geriatric assessment reveals a poor tolerance to

chemotherapy. In conclusion, this study is very useful for clinicians in their practice”.

DOI: 10.3410/f.718106825.793486609

ResearchGate has not been able to resolve any citations for this publication.

ResearchGate has not been able to resolve any references for this publication.

Abstract